Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review

• Published in: Transplantation reviews (Philadelphia, Pa.) Vol. 37; no. 4; p. 100792
• Main Authors: Annamalai, Chandrashekar, Kute, Vivek, Sheridan, Carl, Halawa, Ahmed
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-12-2023
• Subjects: Bone marrow transplantation; Chimerism; Dendritic cells; Hematopoietic stem cell transplantation; Mesenchymal stromal cells; T regulatory cells; Transplantation tolerance induction; Transplantation tolerance induction; Dendritic cells; Treg; Bone marrow transplantation; BMT; IS; TLI; T regulatory cells; Mesenchymal stromal cells; Chimerism; MSC; HSCT; Hematopoietic stem cell transplantation; DC
• DOI: 10.1016/j.trre.2023.100792
• EISSN: 1557-9816
• ISSN: 0955-470X; 1557-9816

Despite its use to prevent acute rejection, lifelong immunosuppression can adversely impact long-term patient and graft outcomes. In theory, immunosuppression withdrawal is the ultimate goal of kidney transplantation, and is made possible by the induction of immunological tolerance. The purpose of this paper is to review the safety and efficacy of immune tolerance induction strategies in living-donor kidney transplantation, both chimerism-based and non-chimerism-based. The impact of these strategies on transplant outcomes, including acute rejection, allograft function and survival, cost, and immune monitoring, will also be discussed.
Databases such as PubMed, Scopus, and Web of Science, as well as additional online resources such as EBSCO, were exhaustively searched. Adult living-donor kidney transplant recipients who developed chimerism-based tolerance after concurrent bone marrow or hematopoietic stem cell transplantation or those who received non-chimerism-based, non-hematopoietic cell therapy using mesenchymal stromal cells, dendritic cells, or regulatory T cells were studied between 2000 and 2021. Individual sources of evidence were evaluated critically, and the strength of evidence and risk of bias for each outcome of the transplant tolerance study were assessed.
From 28,173 citations, 245 studies were retrieved after suitable exclusion and duplicate removal. Of these, 22 studies (2 RCTs, 11 cohort studies, 6 case-control studies, and 3 case reports) explicitly related to both interventions (chimerism- and non-chimerism-based immune tolerance) were used in the final review process and were critically appraised. According to the findings, chimerism-based strategies fostered immunotolerance, allowing for the safe withdrawal of immunosuppressive medications. Cell-based therapy, on the other hand, frequently did not induce tolerance except for minimising immunosuppression. As a result, the rejection rates, renal allograft function, and survival rates could not be directly compared between these two groups. While chimerism-based tolerance protocols posed safety concerns due to myelosuppression, including infections and graft-versus-host disease, cell-based strategies lacked these adverse effects and were largely safe.
There was a lack of direct comparisons between HLA-identical and HLA-disparate recipients, and the cost implications were not examined in several of the retrieved studies. Most studies reported successful immunosuppressive weaning lasting at least 3 years (ranging up to 11.4 years in some studies), particularly with chimerism-based therapy, while only a few investigators used immune surveillance techniques. The studies reviewed were often limited by selection, classification, ascertainment, performance, and attrition bias.
This review demonstrates that chimerism-based hematopoietic strategies induce immune tolerance, and a substantial number of patients are successfully weaned off immunosuppression. Despite the risk of complications associated with myelosuppression. Non-chimerism-based, non-hematopoietic cell protocols, on the other hand, have been proven to facilitate immunosuppression minimization but seldom elicit immunological tolerance. However, the results of this review must be interpreted with caution because of the non-randomised study design, potential confounding, and small sample size of the included studies. Further validation and refinement of tolerogenic protocols in accordance with local practice preferences is also warranted, with an emphasis on patient selection, cost ramifications, and immunological surveillance based on reliable tolerance assays.
•Chimerism- and non-chimerism-based immune tolerance strategies were reviewed in transplant recipients•Both strategies allowed for safe discontinuation of immunosuppressive medications with comparable rejection rates and allograft survival•The myelosuppression-related risk tended to be lower in non-chimerism-based tolerance regimens•Most studies reviewed were limited by small sample sizes, and only a few examined cost implications and immune surveillance techniques•Further validation of the tolerogenic protocols is warranted in large-scale studies